The Effect of Neoadjuvant Chemotherapy on Locally Advanced Gastric Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01444755|
Recruitment Status : Unknown
Verified September 2011 by Atilla Celik, Haydarpasa Numune Training and Research Hospital.
Recruitment status was: Active, not recruiting
First Posted : October 3, 2011
Last Update Posted : October 3, 2011
|Condition or disease|
Adenocarcinoma of the stomach ranks as the fourth most commonly diagnosed cancer and as the second leading cause of cancer-related death in the world. Radical resection with free-margin gastrectomy and extended lymphadenectomy is the preferred surgical strategy in Japan and Asian centers.
Unfortunately, only one-half of surgically treated patients with gastric cancer will achieve a complete resection without residual disease (R0) resection. Moreover, due to, the absence of routine screening programs for gastric cancer, the majority of the patients will be symptomatic at the time of diagnosis in our country.
Additionally, recent treatment strategies were focused for downsizing or decreasing to loco-regional recurrence.
In this reason, we hypothesize that preoperative chemotherapy may improve the R0 resection rate or disease free and/or overall survival rate.
|Study Type :||Observational|
|Estimated Enrollment :||80 participants|
|Observational Model:||Case Control|
|Official Title:||Neoadjuvant Chemotherapy Versus Surgery Alone in Locally Advanced Gastric Cancer: A Randomized Controlled Study|
|Study Start Date :||January 2009|
|Estimated Primary Completion Date :||December 2011|
|Estimated Study Completion Date :||April 2012|
This arm will take a neoadjuvant chemotherapy regimen previous gastrectomy operation.
Surgery will be performed in patients of this arm.
- Survival [ Time Frame: After 2 years from therapy ]
Biospecimen Retention: None Retained
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01444755
|Haydarpasa Numune Training and Research Hospital|
|Istanbul, Turkey, 34668|
|Principal Investigator:||Atilla Celik, M.D.||Haydarpasa Numune Teaching & Research Hospital, Affiliated by Ministery of Health of Turkey|